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APC/C – anaphase promoting complex/cyclosome 
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MDM2 – mouse double minute 2  
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Centrosomes duplicate only once in coordination with the DNA replication cycle and have an important role 
in segregating genetic material. In contrast, the majority of cancer cells have centrosome aberrations including 
supernumerary centrosomes and this correlates with aneuploidy and genetic instability. The tumour 
suppressors p16 (CDKN2A) and p15 (CDKN2B) (encoded by the familial melanoma CDKN2 locus) inhibit 
CDK4/6 activity and have important roles in cellular senescence. p16 is also associated with suppressing 
centrosomal aberrations in breast cancer; however, the role of p15 in centrosome amplification is unknown. 
Here we investigated the relationship between p15/p16 expression, centrosome number abnormalities and 
melanoma progression in cell lines derived from various stages of melanoma progression. We found that 
normal human melanocyte lines did not exhibit centrosome number abnormalities whereas those from later 
stages of melanoma did. Additionally, under conditions of S-phase block, p15 and p16 status determined 
whether centrosome overduplication would occur. Indeed, removal of p15 from p16-negative cell lines derived 
from various stages of melanoma progression changed cells that previously would not overduplicate their 
centrosomes into cells that did. While this study used cell lines in vitro, it suggests that, during clinical 
melanoma progression, sequential loss of p15 and p16 provides conditions for centrosome duplication to 







Extra centrosomes are frequently observed in solid tumours including melanomas and this centrosome 
amplification correlates with aneuploidy and genetic instability (Brinkley, 2001, Charters et al., 2011, Lingle 
et al., 2002, Pihan et al., 1998). A mechanistic link between these organelles and tumorigenesis was first 
proposed by Boveri over a century ago (Boveri, 1914, Boveri, 2008). The abnormal spindle structures he 
predicted have been observed in clinical samples. They are eventually resolved into bipolar spindles but the 
delay leads to lagging chromosomes which are easily damaged (Ganem et al., 2009). The centrosome is 
normally duplicated in S phase, separated into two centrosomes in G2, with each centrosome contributing to 
one of the two spindle poles in M phase. A normal cell therefore contains a maximum of two centrosomes; 
any more are supernumerary. 
 The root cause of extra centrosomes in tumour cells has been the subject of debate for some time (Nigg, 
2002). p53 deficiency has been shown to lead to centrosome amplification through excessive duplication of 
the existing, component centrioles (Fukasawa et al., 1996, Prosser et al., 2009). It has also been proposed that 
in many cases cytokinesis failure, which is tolerated in p53-deficient cells, results in cells with tetraploid DNA 
and an extra centrosome from the previous cell cycle (Borel et al., 2002, Meraldi et al., 2002). However, such 
accumulated centrosomes do not persist in cell culture (Krzywicka-Racka and Sluder, 2011). Centrosome 
amplification – the presence of supernumerary centrosomes - has therefore been proposed to occur by two 
main routes: overduplication, in which the normal process of centriole duplication is repeated before cell 
division, giving four or more centrioles (two or more centrosomes); and accumulation, in which cells abort 
cell division sometime after S-phase so the cell arrests with double the chromosome as well as 
centrosome/centriole complement (Nigg, 2002). In melanoma, p53 mutations are significantly less common 
compared to the frequency observed in most other cancers so, in either case, the abnormal numbers of 
centrosomes in melanoma cannot be attributed to p53 loss (Fecher et al., 2007).  
One example of genuine, clinical centrosome overduplication is in cervical carcinoma, 90% of cases 
of which are caused by HPVs (zur Hausen, 1996). Oncogenic HPVs encode two proteins, E6 and E7, that 
effectively remove p53 and the RB family proteins respectively (Duensing and Munger, 2003). RB 
inactivation has a direct effect on centrosome duplication through activation of the E2F transcription factor 
family and initiation of expression of S-phase proteins, including CDK2 and associated cyclins (Meraldi et 
al., 1999). CDK2-cyclinA/E is a powerful driver of centrosome duplication (Hinchcliffe et al., 1999, Meraldi 
et al., 1999). By selective molecular marking of old versus new centrioles, Duensing and colleagues were able 
to show that E7 expression causes centrosome overduplication (as opposed to centrosome accumulation) 
(Duensing et al., 2008, Duensing and Munger, 2003). 
 The CDKN2 locus, located on chromosome 9p21, encodes three distinct tumour suppressor proteins: 
p16 (INK4A) encoded by CDKN2A, p15 (INK4B) encoded by CDKN2B and p14ARF (p19ARF in mouse) 
encoded by an alternative reading frame of CDKN2A (Hannon and Beach, 1994, Quelle et al., 1995). p16 and 
p14ARF have mirror image roles to HPV E6 and E7.  p16 binds to and inactivates CDK4/6 so preventing RB 
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inactivation and cell cycle initiation (Serrano et al., 1993). p14ARF binds to and inactivates MDM2, thus saving 
p53 from proteolytic degradation (Pomerantz et al., 1998, Sherr and Weber, 2000). Together, the two proteins 
act as brakes on the cell cycle (Bennett, 2003, Sviderskaya et al., 2003). Loss of p16 leads to an apparent 
increase in centrosome number but this has been ascribed to splitting of the centrosome into separate centrioles 
(McDermott et al., 2006). Like p16, p15 is involved in inhibiting CDK4/6 by binding to a non-catalytic site 
of these kinases (Krimpenfort et al., 2007, Pavletich, 1999). Mice deficient for all three genes encoded by the 
CDKN2 locus develop a wider spectrum of tumours than those lacking only p16 and p19ARF.  
 Loss of either the CDKN2A locus or the entire CDKN2 cluster is frequently observed in human cancers 
(Orlow et al., 1999). It is particularly prevalent in melanomas (Bennett, 2003). Sequential loss of alleles 
encoding p16 has been proposed to contribute to the progression from normal melanocytes to malignant 
melanoma via benign nevi, dysplastic nevi, radial growth phase (RGP) and vertical growth phase (VGP) stages 
(Bennett, 2008, Ha et al., 2008). 
 The close mechanistic link between these genes, known to be mutated in cancer, and the centrosome 
duplication pathway would suggest that their loss may be responsible for the extra centrosomes seen in 
melanoma. Decreased p16/15 levels would result in increased CDK4/cyclin D activity, reduced inhibition of 
E2F by RB, and increased CDK2 activity, driving centrosome overduplication. It would follow that 
centrosome numbers should also increase with melanoma progression as p16 and/or p15 expression is 
progressively lost.  
 The resources of the Wellcome Trust Functional Genomics Cell Bank at St George’s, University of 
London, offered a good opportunity to test these two hypotheses in melanoma-derived cell lines. While these 
cell lines are not primary cells from melanomas, they will be very close in genotype to such cells and serve as 
a good model for clinical melanoma. 
  
Results 
Centrosome numbers at different stages of tumorigenesis 
To find out if cells from later stages of melanoma would display increased centrosome numbers, cells were 
stained with an anti-g-tubulin antibody that binds to the material around each centriole, each centrosome 
therefore showing as two punctae of staining. 
 Figure 1A shows the percentage of cells that expressed an abnormal (>3) number of centrosomes 
across melanocyte, RGP, VGP and metastatic melanoma lines. Centrosome amplification was observed in 
several cell lines, notably RGP lines SGM2 and SGM4 (Figure 1B), nearly a quarter of whose cells had three 
or more centrosomes. No melanocyte lines displayed substantial centrosome amplification. As a set, 
melanoma cell lines had higher levels of centrosome amplification than melanocytes (Figure 1C). However, 
all stages of melanoma progression included cell lines where very few cells had supernumerary centrosomes.  
 
Ploidy of cells displaying centrosome amplification 
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To distinguish between the two routes to centrosome amplification - overduplication and accumulation - we 
first compared the DNA content of cells that displayed centrosome amplification with those from the same 
cell line that did not, by quantification of propidium iodide staining, the analysis used by Meraldi et al. (2002). 
 Of the seventeen cell lines examined, all showed significantly higher DNA content in cells with three 
or more centrosomes than in those with two or one (Figure 2). If we calculate the ratio of DNA content of 
cells with centrosome amplification: normal cells, we see that all but one line have ratios in the range 1.5x to 
2.5x. Six lines have a ratio of 2x or above. In these cases, we can confidently assign the increase in centrosome 
number to accumulation. In the other lines, the increase in DNA content could be due to a dividing 
subpopulation that has acquired and then reduced a tetraploid DNA complement while retaining some excess 
centrosomes.   
 
p15 and p16 expression in cell lines from different stages of melanoma progression 
In case there was a relationship between centrosome amplification and p15 and/or p16 status rather than 
melanoma stage, we determined, by Western blotting, the p15 and p16 levels in all cell lines used (Figure 3).   
The normal (Nohm) melanocytes, which will eventually senesce, were all positive for both p15 and p16 but 
expression was relatively low, expected for passage number 15-25.  Either p16 alone or both p15 and p16 
together were lost from pre-metastatic melanoma lines. Even at the RGP stage, some lines had lost expression 
of both proteins. All metastatic lines were double negative for p15 and p16 (p15- p16-).  Progressive loss of 
p15 and p16 is therefore observed as melanoma develops but tumour stage is not an absolute predictor of p15 
and p16 status, neither is p15 and p16 status a predictor of whether centrosome amplification is observed. 
 
Susceptibility of cells to centrosome overduplication in relation to their p15/p16 status 
Hydroxyurea treatment of cells, which imposes an S-phase block, causes centrosome overduplication in a 
number of cell lines and is the basis of the centrosome duplication assay that has been used to examine how 
centrosome duplication is controlled (Balczon et al., 1995, Habedanck et al., 2005). We sought to test if 
p15/p16 status had an effect on whether melanoma cell lines would overduplicate centrosomes in this assay. 
We confirmed that hydroxyurea treatment caused an S-phase block in these two cell lines by FACS analysis 
(data not shown). 
 All normal melanocyte lines - Nohm1, Nohm 4, Nohm 5 and Nohm 6, all p15 and p16 positive – 
showed no significant change in the proportion of cells with centrosome number abnormalities (Figure 4). All 
four p15+ p16- cell lines also showed no change in frequency of cells with at least 3 centrosomes in the 
centrosome duplication assay. 
 All eight p15 and p16 double negative lines overduplicated centrosomes (yellow in Fig. 4). Untreated 
cells displayed a low level of centrosome amplification whereas hydroxyurea-treated cells displayed a 
significant increase in centrosome numbers. This strongly suggests that both p15 and p16 need to be absent 
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for the centrosome duplication and DNA replication cycles to be uncoupled and centrosome overduplication 
to occur.  
 
Effect of altering p15 (and p16) expression levels on centrosome overduplication 
If loss of p15 is important for centriole overduplication, provided p16 is also absent, then depletion of p15 
from p15+p16- cells should result in overduplication whereas expression of p15 in p15-p16- cells should 
inhibit it. 
We depleted p15 and p16 by siRNA, judging efficacy by Western blotting of cell extracts from Nohm5 
cells transfected with respective siRNAs (Figure 5A). We complemented loss of p15 by transfection of cells 
with an expression construct for p15. This was judged effective by Western blotting of extracts from A375P 
cells treated in this way.  
In the case of p15+p16- cells now depleted of p15, centrosome numbers increased significantly during 
the centrosome duplication assay (Figure 5C), although the level of overduplication in Hermes 1 was modest. 
In the case of p15-p16- cells now complemented in trans with p15, centrosome overduplication was now 
significantly inhibited (Figure 5C). This was true both in the case of a line carrying the BRAF oncogene – 
A375P – and a line carrying the NRAS Q61K oncogene – DX3. Nohm4 cells, depleted of both p15 and p16 
by siRNA showed a very modest increase in centrosome overduplication. In all cases, results were consistent 
with the proposal that for centrosome overduplication to occur, both p15 and p16 need to be absent.   
 
Mechanism behind supernumerary centrosomes 
Centrosome amplification could result from one of three processes: accumulation (after failed division) 
overduplication and premature splitting of a duplicated centrosome. Following the example of Duensing et al. 
(Duensing et al., 2008), we stained mother centriole appendages to distinguish between these three outcomes, 
using an antibody to ODF2 (Lange and Gull, 1995) (Figure 6A, first row). 
According to the number and staining of fluorescent puncta, cells with supernumerary centrosomes 
were classified as follows: split after duplication - 1 punctum of ODF2 with 3 or 4 separate puncta of γ-tubulin 
(Figure 6A, second row); overduplication - 1 punctum ODF2 with 5 or more puncta of γ-tubulin (Figure 6A, 
third row); accumulation - 2 puncta of ODF2 with 4 or more puncta of γ-tubulin (Figure 6A, fourth row). 
We observed only a small proportion of cells with duplicated and split centrosomes (Figure 6B, C). 
Treatment with siRNA to p15 or p16 alone or both had no effect on the level of duplicated and split 
centrosomes compared to that seen in control (scrambled) siRNA-treated cells. Overduplication accounted for 
all the extra centrosomes observed (Figure 6B, C).  
 
Discussion  
Expression of CDKN2 is frequently lost in human melanoma. Moreover, in approximately 20% of all 
melanomas p16 is expressed but remains inactive due to mutations (Bennett, 2016). We examined cell lines 
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derived from different stages of melanoma progression. Melanocyte lines were positive for both p15 and p16 
but at low levels.  However, RGP and VGP melanomas varied in p15 and p16 status. RGP lines were a mixture 
of p15 positive and p16 negative (p15+ p16-), p15 and p16 double positive (p15+ p16+) and p15 and p16 
double negative lines (p15- p16-). Almost all VGP and all metastatic lines had lost expression of both proteins.  
 Supernumerary centrosomes are frequently observed in human cancers. It is possible that they arise 
either owing to cytokinesis failure and accumulation of extra centrosomes or owing to deregulated centrosome 
duplication. Although we observed a step increase in the proportion of cells with extra centrosomes from 
normal melanocytes to the various melanoma lines, we found that the expression status of p15 and p16 per se 
cannot predict the degree of centrosome supernumerary aberrations in cell lines from each stage of melanoma 
progression. Indeed, it appears that the supernumerary centrosomes observed in many cultured lines were due 
to mitotic failure leading to centrosome accumulation alongside tetraploidy. Indeed, RGP cells seem to go 
through a crisis before progressing the VGP stage, with anaphase bridges and mitotic failures, which fits with 
these results (Bennett, 2016, Soo et al., 2011). This might explain the step-change in centrosome numbers 
between normal melanocytes and melanoma cells of all stages, the first of which is RGP.  
p15/p16 status did affect whether these cells overduplicated centrioles under the centrosome 
duplication assay that has been extensively used to determine the contribution of centrosome proteins and cell 
cycle regulators. For centrosome overduplication to occur, both p15 and p16 needed to be absent. The presence 
of either or both prevents overduplication. This effect is independent of the oncogene present as lines carrying 
either BRAF or NRAS oncogenes behaved in the same way. In assay conditions, genuine overduplication is 
observed as opposed to the accumulation seen in continuous culture. It is notable in this regard that it has been 
reported that the extra centrosomes observed in melanoma biopsies are due to overduplication rather than 
accumulation (Denu et al., 2018) so are closer to our assay results. This suggests that p15 and p16 may have 
a similar effect in melanoma. 
 The response of many widely used model cell lines to this centrosome overduplication assay varies. 
Some e.g. U2OS overduplicate centrioles whereas others e.g. HeLa do not. Although hydroxyurea treatment 
should induce an S-phase block by inhibiting DNA synthesis, Khodjakov has proposed that cells that 
overduplicate centrioles under these conditions slip into a G2-like state rather than an S-phase arrest (Loncarek 
et al., 2010). In such cells, high PLK1 activity in G2 allows procentrioles to mature, disengage from parent 
centrioles and subsequently reduplicate. Fry and colleagues showed that APC/C and CDK2 activities cycle 
under these conditions (under G2 arrest PLK1 degrades the APC/C inhibitor, thus activating APC/C), leading 
to rounds of centriole disengagement and duplication (Prosser et al., 2012). The question still remains why 
some cells e.g. U2OS slip into this quasi-G2 state whereas others e.g. HeLa stay blocked in S-phase. 
The status of p15/p16 expression could be relevant to this question. Previously, it was shown that p16 
overexpression in U2OS cells suppresses overduplication under hydroxyurea block (Meraldi et al., 1999). This 
overexpression is also complementing the genetic lesion in these cells, which are p16-negative (data not 
shown). In contrast, HeLa cells are often used as a positive control for CDKN2 expression as this line is both 
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p15- and p16-positive (Figure 3). Since HeLa cells will overduplicate centrioles when regulators such as PLK4 
are overexpressed in these cells or when blocked in G2 (Loncarek et al., 2010, Meraldi et al., 1999), this 
implies the limiting factor is upstream in the centriole duplication pathways or earlier in the cell cycle. p15 
and p16 activity could be that factor. Loss of p15 and/or p16 would result in increased activity of CDK4/6-
cyclinD, whose protein levels are maintained throughout the cycle, and could provide the drive to push cells 
into a quasi-G2 state in which centrosome duplication cycle continues irrespective of the blocked DNA cycle. 
There are reports showing that CDK4/6-cyclinD plays a role in progression through G2 and contributes, with 
CDK2, to centrosome duplication (Adon et al., 2010, Gabrielli et al., 1999). 
In tumour-derived cells one would not expect p15 / p16 status to be the only determinant of centrosome 
overduplication but a brake that needs to be off for overduplication to occur. Accordingly, centrosome 
overduplication must depend on other oncogenic changes but require p15 and p16 loss. Interplay between the 
CDKN2 proteins and other key drivers of melanoma progression such as BRAF and NRAS mutations (Davies 
et al., 2002) must be required for centrosome overduplication. Indeed, many of the cell lines in this study are 
known to have these oncogenic mutations:  BRAF V600E in the SGM2-4 and A375P lines or NRAS Q61K 
in the SGM5 and DX3 lines (Soo et al., 2011). Furthermore, we sequenced the relevant genomic fragments 
covering these mutations in the WM-98-1 line and found it to possess the BRAF V600E mutation 
(supplementary table S1). Therefore, the SGM2, WM-98-1 and A375P lines all possess the BRAF V600E 
mutation and both overduplicate centrioles when p15 and p16 are absent. However, this effect is not limited 
to the BRAF oncogene as we obtain the same results with DX3 cells that carry the NRAS oncogene. Future 
work to test the hypothesis that the combination of BRAF or NRAS oncogenes and p15/p16 loss is sufficient 
for centrosome overduplication to occur will necessitate the creation of new stable cell lines, derived from 
normal melanocytes, that harbour this combination of mutations but lack the other mutations that may be 
present in melanoma lines.  
 In melanoma, mutations/deletions/silencing of the CDKN2A locus often results in loss of both p16 and 
p14ARF. Loss of p14ARF affects p53 stability via increased MDM2 activity, although p14ARF is also known to 
have p53-independent mechanisms of action (Ha et al., 2007).  p53 mutations in melanoma are themselves 
rare (Bennett, 2016, Gembarska et al., 2012). However, MDM4, another inhibitor of TP53, has been found to 
be upregulated in 69% of human melanomas (Gembarska et al., 2012) and in all the melanoma cell lines 
examined in that same study. Therefore, cells in which the entire CDKN2 cluster is lost face the perfect storm 
for centrosome amplification. With centriole overduplication uninhibited and a reduced ability to respond to 
errors in centrosome duplication, supernumerary centrosomes can be generated and tolerated. While our study 
has been conducted on cultured cell lines derived from melanomas, it suggests that, in melanoma, the very 
mutations that allow cells to escape normal growth controls, including cellular senescence, also allow 
centrosome duplication to become deregulated. It will be interesting to see if clinical samples of early 
melanomas also display correlation between loss of p15 and p16 activity and increased centrosome numbers. 
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Materials and Methods 
Cell culture 
Human melanoma cell lines were grown in RPMI 1640 medium (Invitrogen, UK) supplemented with foetal 
calf serum (10%, Invitrogen), L-glutamine (2 mM, Invitrogen), penicillin/streptomycin (100 U/ml and 100 
µg/ml, respectively, Sigma) and extra phenol red (7.5 µg/ml, Sigma) at 37OC with 10% CO2. Human normal 
and immortal melanocyte lines were grown as above with the addition of 200 nM 12-O-tetradecanoyl phorbol 
13-acetate (Sigma), 200 pM cholera toxin (Sigma), 10 ng/ml human stem cell factor (Invitrogen) and 10 nM 
endothelin 1 (Bachem, Germany). To assay for centrosome duplication, fresh medium was supplemented with 
4 mM hydroxyurea (Sigma) and cells were incubated for 48 h before fixing as below. 
 
Immunostaining 
Cells were fixed at 75% confluence in -20OC methanol (Fisher Scientific) for 5 min then blocked with 1% 
BSA (Sigma) prepared in complete PBS for 20 min. Cells were probed with antibodies for one hour at room 
temperature. Primary antibodies used were against: γ-tubulin (1:1000, Sigma) and ODF2 (1:500, Abcam). 
Secondary antibodies were Alexa Fluor 488 goat anti-mouse IgG and/or Alexa Fluor 594 goat anti-rabbit IgG 
(1:200, Invitrogen). The nuclei were stained with propidium iodide (1 µg/ml, Sigma) or DAPI (1µg/ml, 
Invitrogen). Cells were mounted in Citifluor (Agar Scientific). Coverslips were washed with complete PBS 
between steps. Images were taken using an Axioplan 2 epifluorescence microscope and AxioVision 3 software 
(Carl Zeiss). Images of cells stained with propidium iodide were further analysed using the AxioVision 3 
software to quantify DNA content for each nucleus. 
 
Western blotting 
Cells were lysed using lysis buffer containing 50 mM Tris – pH 8, 150 mM NaCl, 2 mM EDTA, 1% Triton-
X100, 1% SDS and 1× protease inhibitor (Complete Mini Cocktail Tablets, Roche). The lysates were 
homogenized then centrifuged for 15 min at 6613 x g. Protein concentration was determined using the Pierce 
BCA Protein assay kit (Thermo Scientific). 30-40 µg of protein from each sample were resolved by a 15% 
polyacrylamide gel and wet transferred to a PVDF membrane (Millipore). The membranes were blocked in 
PBS containing 5% dried milk powder and 0.1% Tween-20 for 1 hour at room temperature and then incubated 
in anti-p15 (1:1000, Santa Cruz) or anti-p16 (1:1000, Cell Signalling) primary antibody overnight at 4OC. 
Following incubation in HRP-conjugated anti-mouse (for p15) or anti-rabbit (for p16) secondary antibody 
(1:2000, Cell Signalling) for 1 hour at room temperature, proteins were detected using ECL (GE Healthcare 
Life Sciences). Two bands for p15 were revealed as previously described by Fuxe et al. (Fuxe et al., 2000). 
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To re-probe the blots with a loading control antibody, the membranes were stripped for 10 min at room 
temperature in stripping solution (Millipore) and blocked for 1 hour prior to re-probing for β-actin (1:1000, 
Cell Signalling).  
 
Transfection of cultured cells 
Nohm 4, WM-98-1 and SGM2 cells were transfected using DharmaFECT transfection reagent 2 (0.1 µl/100 
µl well, ABgene) with ON-TARGET plus SMART pools of siRNAs directed against human CDKN2A and/or 
CDKN2B (25 nM) as per the manufacturer’s guidance. A375P cells were transfected with pBabe-puro-hp15 
(a kind gift from Prof Gordon Peters, CRUK, London Research Institute) using Lipofectamine 2000 
transfection reagent (Life Technologies) for 24 h using 2 µl reagent and 1µg of plasmid DNA per 500 µl as 
per the manufacturer’s guidance. 
 
FACS analysis 
Between 0.5 to 1x106 cells were grown in 6-well plates and treated as described. Cells were detached from 
the surface, pelleted and washed twice in PBS before fixing with 70% ethanol for 1 hour at 4°C, with the 
ethanol solution added while the cells were mixed on a vortex. Cells were stained with 1µg/ml DAPI. A Canto 
II FACS (Beckton Dickinson) was used for sample analysis, according to manufacturer’s instructions, with 




All data are expressed as mean ± SEM (Standard Error of the Mean) except where specified. Student’s t-test 
was applied to determine statistical significance, or ANOVA (LSD test) where stated.  In all cases, statistical 




No patient samples were used in this study, only cell lines, so patient consent was not required and these 
materials are not classified as relevant material under the UK Human Tissue Act (2004). 
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Legends to Figures 
Figure 1. Centrosome abnormalities in cell lines from different stages of melanoma progression. (A) Bar 
graph showing the percentage of cells with 3 or more centrosomes in melanocyte/RGP/VGP and metastatic 
melanoma lines. At least 100 cells were analysed per experiment. (B) Immunostaining of centrosomes (γ-
tubulin, green) and nuclei (propidium iodide, red) in melanocyte cell line Nohm 1, RGP cell lines SGM2 and 
SGM4 and in VGP cell line WM-98-1. Insets show centrosomes magnified. Scale bar 10 µm. (C)  Bar graph 
representing combined data from (A) showing the proportion of centrosome number abnormality (3 or more 
centrosomes). Mean percentage of cells with 2 or fewer and 3 or more centrosomes across five melanocyte 
lines, five RGP lines, four VGP lines and three metastatic melanoma lines. Statistical significance is marked 
as p<0.05 (*), p<0.01 (**) and p<0.001 (***).  The level of statistical significance shown is that relative to 
the % of cells in melanocyte lines for each category (2 or fewer and 3 or more centrosomes).  
Figure 2. Relationship between centrosome number and DNA content. A) Comparison of DNA content 
between cells with 2 or fewer and 3 or more centrosomes, in cell lines from different stages of melanoma 
progression. Propidium iodide was used to stain nuclei. The nuclear area of each cell (at least 100 cells for 
each cell line) was analysed to determine the differences in propidium iodide fluorescence intensity between 
the two groups of cells. B) Ratio of DNA content, cells with centrosome amplification: normal cells, using 
DNA content from (A). 
Figure 3. p15 and p16 expression in cell lines. Western blotting analysis of p15 (A) and p16 (B) expression 
in melanocyte, RGP, VGP and metastatic melanoma lysates, respectively. 40 or 30 µg protein per well were 
resolved from each sample. HeLa cell line represented a positive and negative control, respectively. β-actin 
was probed as a loading control on all blots.  
Figure 4. Results of the centrosome duplication assay, using melanoma cell lines. Effect of hydroxyurea 
(HU)-induced S-phase block (4mM for 48h) on centrosome duplication for all cell lines. Statistical 
significance is marked as p<0.001 (***), p<0.01 (**) and p<0.1 (*). The table indicates the p15 and p16 
expression status (+: cell line expressing p15 or p16; -: cell line null for p15 or p16). 
Figure 5. Effect of altering p15/p16 levels on the outcome of  the centrosome duplication assay. Depletion 
or restoration of expression of p15/p16 by transient transfection using CDKN2A/B siRNA or expression 
plasmid and its effect on centrosome duplication.  (A) Western blotting analysis of p15 (left) and p16 (right) 
expression in A375P melanoma cells after transfection with p15 expression construct pBabe-puro-hp15. B) 
Western blotting analysis of p15 and p16 expression in Nohm5 cells post transfection with respective siRNAs 
(72 h). (C) Centrosome (over)duplication in melanoma lines depleted of or complemented with p15 (and p16). 
Nohm4 cells were depleted of both p15 and p16. Hermes1, SGM2 and WM-98-1 cells were depleted of p15. 
A375P and DX3 cells were complemented with p15 by transfection with a plasmid encoding p15. All 
differences statistically significant at p<0.05 or less.  
Figure 6. Type of centrosome amplification observed in p15- p16-depleted cells. A) Centrosome 
amplification in p15- and p16-depleted cells. ODF2 (red, mother centriole) and γ-tubulin (green, both 
15 
 
centrioles) staining of centrosomes in normal cells and abnormal cells (duplicated and split, overduplicated 
and accumulated centrosomes). The nuclei are stained with DAPI (blue). B, C) Nature of centrosome 
amplification in p15- and p16-depleted cells. Bar graphs of normal vs. duplicated and split vs. overduplicated 
vs. accumulated centrosomes in WM-98-1 (B) and SGM2 (C) cell lines post siRNA transfection followed by 
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